The particle-count version of LDL — captures cardiovascular risk that LDL-C alone can miss, especially in insulin resistance.
LDL-P counts the actual number of LDL particles circulating, not the cholesterol mass they carry. Two people with the same LDL-C can have very different particle numbers — and risk tracks with particle count, not cholesterol mass. LDL-P is the NMR-based equivalent of ApoB (which is immunoassay-based); both measure the same underlying biology.
Discordance between LDL-C and LDL-P is common in metabolic syndrome, T2D, and insulin resistance — these patients often have small-dense LDL, meaning many particles but less cholesterol per particle. LDL-C looks "fine" while LDL-P is elevated.
LDL-P is influenced by: genetics (familial hyperlipidemia), diet (saturated fat and refined carbs raise it), insulin resistance (drives small-dense LDL), thyroid status (hypothyroidism elevates it), statins (major reducer), PCSK9 inhibitors (further reducer), and body composition. GH-axis peptides can shift particle size distribution.
Many optimization users draw LDL-P alongside ApoB if their lab offers NMR (LabCorp NMR LipoProfile is the reference assay). Not all labs run it. If available, LDL-P or ApoB should be the primary LDL-tracking marker, not LDL-C alone. Recheck at 12 weeks after any lipid-affecting change.
Upload any lab PDF and MyProtocolStack maps your values to LDL-P and 40+ other biomarkers. StackAI interprets the trend in context of your protocol.
Start tracking →Informational only — not medical advice. Reference ranges vary by lab and individual context. Work with a licensed provider to interpret your specific results.